Form 4: Edwards Lifesciences Executive Bobo Jr. Reports Stock Transactions

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Summary

• Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 7, 2025, 851 shares of common stock were disposed of at a price of $74.92.
• On May 8, 2025, 8,375 shares of common stock were acquired.
• As of May 8, 2025, Bobo directly owns 53,742.3707 shares of common stock.
• Bobo indirectly owns 38,817.6991 shares through a 401(k) and 135,152 shares through a trust.
• Bobo was granted an option to acquire 47,000 shares of common stock at an exercise price of $74.63, exercisable starting June 8, 2025, and expiring on May 7, 2032.
• Bobo was also granted 8,375 performance rights, vesting on May 8, 2028, with the actual number of shares vesting dependent on performance goals.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The granting of stock options and performance rights to a key executive suggests an incentive alignment with the company's long-term performance.

Future Outlook

The vesting of restricted stock units and performance rights is contingent upon continued employment and achievement of performance goals over the next several years.

Industry Context

Stock transactions by company executives are routinely monitored as they can provide insights into management's perspective on the company's valuation and future prospects. This filing is a standard disclosure required by the SEC.

Comparison to Industry Standards

• Executive compensation packages including stock options and performance rights are common in the medical device industry, aligning executive incentives with shareholder value.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting equity.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, performance rights, Edwards Lifesciences, stock, transactions